MedTrace Logo

TRx0014 in Patients With Mild or Moderate Alzheimer's Disease

NCT00515333 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 323

Last updated 2008-02-20

No results posted yet for this study

Summary

The primary objective of the study is to investigate the effects of oral TRx0014 at three doses (30, 60 and 100 mg tid) compared with placebo on cognitive ability in patients with mild or moderate dementia of the Alzheimer type. Cognitive ability will be measured by the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog). The primary evaluation will be made at 24 weeks.

Conditions

  • Dementia, Alzheimer Type

Interventions

DRUG

TRx0014

Hard capsule; 60 milligrams; t.i.d.

DRUG

TRx0014

Hard capsule; 30 milligrams; t.i.d.

DRUG

Placebo

Hard capsule; 0 milligrams; t.i.d.

DRUG

TRx0014

Hard capsule, 100 milligrams, t.i.d.

Sponsors & Collaborators

  • TauRx Therapeutics Ltd

    lead INDUSTRY

Principal Investigators

  • Claude M Wischik, MBChB · TauRx Therapeutics Ltd

  • Peter Bentham, MBChB · Queen Elizabeth Psychiatric Hospital, Birmingham, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2007-12-31
Completion
2007-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00515333 on ClinicalTrials.gov